Alexion Pharmaceuticals Inc (ALXN)

ALXN (NASDAQ:Drugs) EQUITY
$142.28
pos +0.00
+0.00%
Today's Range: 139.13 - 146.90 | ALXN Avg Daily Volume: 1,588,200
Last Update: 02/05/16 - 3:59 PM EST
Volume: 0
YTD Performance: -25.41%
Open: $0.00
Previous Close: $146.02
52 Week Range: $130.51 - $208.88
Oustanding Shares: 225,324,303
Market Cap: 32,901,854,724
6-Month Chart
TheStreet Ratings Grade for ALXN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 13 11 11 11
Moderate Buy 1 1 1 1
Hold 3 3 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.38 1.43 1.43 1.43
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 217.94
Price Earnings Comparisons:
ALXN Sector Avg. S&P 500
217.94 218.40 30.32
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-17.97% -20.14% 49.27%
GROWTH 12 Mo 3 Yr CAGR
Revenue 44.00 1.30 0.32
Net Income -78.00 -0.43 -0.17
EPS -79.50 -0.49 -0.20
Earnings for ALXN:
EBITDA 0.80B
Revenue 2.60B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $0.95 $1.05 $4.39 $6.30
Number of Analysts 3 3 3 1
High Estimate $1.01 $1.07 $4.44 $6.30
Low Estimate $0.91 $1.04 $4.35 $6.30
Prior Year $1.07 $1.13 $4.55 $4.39
Growth Rate (Year over Year) -10.90% -6.78% -3.52% 43.51%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Novice Trade: Illumina Real Money Pro($)

ILMN's three-month at-the-money implied volatility is at about the median level.
Bullish
Oct 02, 2015 | 7:50 AM EDT
ALXN was upgraded to Overweight, Morgan Stanley said. $211 price target. Orphan drugs should not face pricing concerns and the company ...
Bearish
Sep 14, 2015 | 8:09 AM EDT
ALXN was downgraded from Overweight to Equal-weight, Barclays said. $205 price target. Expects delays in Strensiq and Kanuma launches. ...
Acquisitions cut into overabundance of companies.
U.S. stocks fell for a second straight session.
Here are healthcare stocks of all shares and sizes with strong charts.
Bearish
Jan 30, 2015 | 7:49 AM EST
Shares of ALXN now seen reaching $186, according to Credit Suisse. Estimates also reduced, given the company's currency headwinds. Neut...

Braving Biotech Real Money Pro($)

Do you need to pick one name?
They are prone to being whipsawed by news.
Bearish
Jan 05, 2015 | 6:36 AM EST
ALXN was downgraded from Overweight to Equal-weight, Morgan Stanley said. $202 price target. Valuation call, as the company has limited...

Columnist Conversations

Flat as a pancake. Thus far, Jim "El Capitan" Cramer doesnt yet get his wish. http://realmoneypro.thestreet.co...
We had expected a recovery in energy prices and better things from the stocks for some time. So far, we have b...
Industrials have seen their revenues and earnings outlook slow in the past year due to a slowing China and a b...
Get your cues from market legends like Jesse Livermore... http://realmoneypro.thestreet.com/dougs-daily-diary?...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.